Results of the economic evaluation of the first study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial.
We present the prospective economic evaluation that served as a secondary endpoint for the FIRST study, a randomized international multicenter trial of patients with severe congestive heart failure. Although the clinical results of this study were disappointing, we demonstrated the feasibility of incorporating prospective economic evaluation in phase III clinical trials.
Schulman
K A
KA
Georgetown University Medical Center, USA.
Buxton
M
M
Glick
H
H
Sculpher
M
M
Guzman
G
G
Kong
J
J
Backhouse
M
M
Mauskopf
J
J
Bell
L
L
Eisenberg
J M
JM
D000368:Aged; D004341:Drug Evaluation / Q000191:economics*; D011464:Epoprostenol / Q000191:economics* / Q000627:therapeutic use; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006333:Heart Failure / Q000188:drug therapy / Q000191:economics* / Q000401:mortality; D006801:Humans; D015337:Multicenter Studies as Topic; D010975:Platelet Aggregation Inhibitors / Q000191:economics* / Q000627:therapeutic use; D011446:Prospective Studies; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis
D010975:Platelet Aggregation Inhibitors; D011464:Epoprostenol